For in vitro diagnostic use. Others Elecsys HE4 IVD Elecsys® HE4 CPS_000482 05950929214 HE4 Elecsys cobas e 100 Elecsys HE4 07613336162316 Reagents, kits 100 tests cobas e 411/601/602 true 07027478190 HE4 Elecsys E2G 100 Elecsys HE4 04015630940219 Reagents, kits 100 tests cobas e 402/801 true 05950929190 HE4 Elecsys cobas e 100 Elecsys HE4 04015630929641 Reagents, kits 100 tests cobas e 411/601/602 true 07027478214 HE4 Elecsys E2G 100 Elecsys HE4 07613336193990 Reagents, kits 100 tests cobas e 402/801 true ms_05950929190 Elecsys HE4 en 10 FF0000000381BE0E FF000000000C530E 05950929190 05950929214 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.It is further intended to be used in conjunction with the Elecsys CA 125 II assay as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 05950929500 Elecsys HE4 en 13 FF000000059B610E FF0000000381BE0E 05950929190 05950929214 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.It is further intended to be used in conjunction with the Elecsys CA 125 II assay as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 07027478500 Elecsys HE4 en 7 FF000000059B640E FF00000004CACB0E 07027478190 07027478214 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.It is further intended to be used in conjunction with the Elecsys CA 125 II assay as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027478500 Elecsys HE4 en 5 FF00000004CACB0E FF00000004BD320E 07027478190 07027478214 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.It is further intended to be used in conjunction with the Elecsys CA 125 II assay as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027478501 Elecsys HE4 en 3 FF00000006CE380E FF00000001E3EF0E 07027478190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 assay values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027478501 Elecsys HE4 en 2 FF000000056C070E FF00000001D7150E 07027478190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 assay values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en